Mesothelioma Treatment Options
Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs, abdomen, or heart, most often linked to asbestos exposure. Understanding the range of mesothelioma treatment options can help patients and their families navigate this complex diagnosis.
Key Takeaways
- Mesothelioma treatment typically combines two or more approaches — surgery, chemotherapy, and radiation therapy — chosen based on the tumor’s location, stage, and cell type.
- The FDA has approved the combination of nivolumab and ipilimumab for unresectable pleural mesothelioma, and pemetrexed paired with a platinum drug remains a standard first-line chemotherapy regimen.
- Side effects differ by treatment type and are managed with supportive care; a dedicated guide on this site covers side-effect management in more depth.
- Treatment prognosis depends on factors such as cancer stage, cell type, and how well the disease responds to therapy — a separate page on this site covers survival outlook specifically.
- Because no single treatment fits every patient, a multidisciplinary care team helps weigh the options, including clinical trials, to find the best-fit plan.
Understanding Mesothelioma Treatment Options
The approach to treating mesothelioma is highly individualized, depending on the cancer’s stage, cell type, location, and the patient’s overall health. A multidisciplinary team of specialists typically collaborates to determine the combination of therapies most likely to help. Treatment usually draws on more than one of the conventional approaches described below.
Surgical Interventions
Surgery is an option for eligible patients, particularly those with earlier-stage disease. The goal is to remove as much of the cancerous tissue as possible. The main surgical procedures include:
- Extrapleural Pneumonectomy (EPP): This extensive operation removes the affected lung, the lining of the lung (pleura), part of the diaphragm, and the lining around the heart (pericardium). It is typically reserved for younger, healthier patients with earlier-stage disease.
- Pleurectomy/Decortication (P/D): A less extensive procedure than EPP, P/D removes the pleura and visible tumor from the lung surface, diaphragm, and pericardium while sparing the lung itself. It’s often used for patients who aren’t candidates for EPP.
Surgery is often followed by chemotherapy or radiation therapy to address any remaining cancer cells and lower the risk that the disease will come back.
Chemotherapy and Radiation Therapy
Chemotherapy and radiation therapy are core components of mesothelioma treatment, often used alongside surgery or as the main treatment for more advanced disease.
- Chemotherapy: The standard first-line regimen combines pemetrexed (Alimta) with a platinum drug, usually cisplatin; carboplatin may be substituted for cisplatin when needed. Chemotherapy can be given before surgery to shrink tumors, after surgery to address remaining cancer cells, or as the primary treatment when surgery isn’t an option, aiming to control tumor growth and ease symptoms.
- Radiation Therapy: This localized treatment directs high-energy rays at the tumor from outside the body. It may be used to shrink a tumor before surgery, target residual cancer cells afterward, or relieve pain and other symptoms in more advanced disease.
Innovative and Emerging Mesothelioma Therapies
Treatment options for mesothelioma continue to evolve as research identifies new drugs and combinations, offering additional possibilities for patients who may not respond to conventional therapies.
Immunotherapy Approaches
Immunotherapy takes a different approach than chemotherapy or surgery: rather than attacking the tumor directly, it activates a patient’s own immune defenses against mesothelioma cells.
- Checkpoint Inhibitors: Nivolumab blocks the PD-1 checkpoint protein, and ipilimumab blocks a different checkpoint called CTLA-4; together they release a stronger immune response against tumor cells. The FDA has approved nivolumab plus ipilimumab as a first-line treatment for adults with unresectable malignant pleural mesothelioma.
- Other Immunotherapy Under Study: Drugs such as durvalumab, which targets the related PD-L1 protein, are being studied in mesothelioma, often paired with chemotherapy.
Targeted Drug Therapies
Targeted therapies interfere with specific molecules involved in tumor growth, aiming at cancer-cell vulnerabilities rather than affecting all rapidly dividing cells the way chemotherapy does.
- Anti-angiogenic Drugs: Bevacizumab (Avastin) targets the process tumors use to form new blood vessels that sustain their growth, and it can be combined with chemotherapy for pleural mesothelioma.
- Other Targeted Agents Under Study: Ramucirumab, which also acts on tumor blood-vessel signaling, is being studied in combination with chemotherapy for mesothelioma that has progressed after earlier treatment.
These newer approaches are often available through clinical trials, giving patients access to treatments tailored to their tumor’s characteristics.
Managing Side Effects of Mesothelioma Treatment
Treatment-related side effects vary with the type and intensity of therapy. Surgery can cause pain, fatigue, infection, blood clots, and breathing difficulties, typically managed with pain control, physical therapy, and monitoring for complications. Chemotherapy commonly causes nausea, fatigue, hair loss, and a temporarily weakened immune system, while radiation therapy can cause skin irritation, fatigue, and localized pain. Immunotherapy is generally better tolerated, but it can trigger immune-related reactions in which the immune system also affects healthy tissue, and these need prompt medical attention.
A comprehensive supportive care plan — covering pain management, nutrition, physical therapy, and psychological support — helps patients cope throughout treatment. A dedicated guide on this site covers managing mesothelioma treatment side effects in more depth.
Mesothelioma Treatment Prognosis and Outlook
Because mesothelioma behaves differently from person to person, treatment prognosis depends on several factors working together, including how well the cancer responds to the chosen therapies, the extent of disease at diagnosis, and the patient’s overall health. A multimodal treatment plan — combining surgery, chemotherapy, radiation, and immunotherapy as appropriate — is generally associated with better outcomes than relying on a single approach alone. A dedicated page on this site covers mesothelioma survival rates and prognosis in more detail, including how outlook varies by stage and cell type.
Frequently Asked Questions
What are the best mesothelioma treatments available today?
There’s no single “best” treatment — the right combination depends on the cancer’s stage, cell type, location, and the patient’s overall health. Many patients receive some combination of surgery (if the tumor can be removed), pemetrexed-based chemotherapy, and radiation therapy, while the FDA-approved combination of nivolumab and ipilimumab is an option for unresectable disease. Clinical trials can also provide access to newer approaches.
How can patients manage mesothelioma treatment side effects?
Side-effect management is tailored to the specific therapy: pain control and physical therapy typically follow surgery, anti-nausea medication supports chemotherapy, and skincare helps with radiation-related skin changes. Immune-related reactions from immunotherapy are managed with specific medications when they occur. Staying in close contact with the care team helps side effects get caught and treated early.
What is the typical mesothelioma treatment prognosis?
Treatment prognosis varies widely and depends on factors such as cancer stage, cell type, and how well the disease responds to therapy. Advances in multimodal treatment, including newer immunotherapy options, have expanded what’s possible for some patients. A dedicated survival-rate and prognosis page on this site takes a closer look at outlook and how it’s assessed.
Sources
